$ACHV
ACHIEVE LIFE SCIENCES, INC. Stock $achv

$achv Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-K Financial Statement

#000156459018004159 Filed on March 01, 2018

Income Statement

Concept	2017 Q4	2017 Q3	2017 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.630M	$1.550M	$2.530M
YoY Change	-29.13%	-16.67%	10.0%
% of Gross Profit
Research & Development	$2.153M	$825.0K	$61.00K
YoY Change	2591.25%	1095.65%	-6.15%
% of Gross Profit
Depreciation & Amortization	$90.00K	$60.00K	$93.00K
YoY Change	125.0%	20.0%	66.07%
% of Gross Profit
Operating Expenses	$2.153M	$825.0K	$61.00K
YoY Change	2591.25%	1095.65%	-99.17%
Operating Profit
YoY Change
Interest Expense	$10.00K	$10.00K	$30.00K
YoY Change	-75.0%	-80.0%	-40.0%
% of Operating Profit
Other Income/Expense, Net	$42.00K	-$7.025M	-$8.000K
YoY Change	-1150.0%	100257.14%	33.33%
Pretax Income	-$3.740M	-$9.400M	-$329.0K
YoY Change	-35.96%	2220.99%	-91.13%
Income Tax	$0.00	-$2.930M
% Of Pretax Income
Net Earnings	-$3.740M	-$6.469M	-$205.0K
YoY Change	669.55%	2313.81%	-15.29%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$62.33M	-$161.8M	-$327.0M
COMMON SHARES
Basic Shares Outstanding	11.95M		30.09M
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.300M	$8.000M	$784.0K
YoY Change	-48.27%	-37.41%	-98.3%
Cash & Equivalents	$5.284M	$8.021M	$24.00K
Short-Term Investments			$760.0K
Other Short-Term Assets	$600.0K	$500.0K	$800.0K
YoY Change	-40.0%	-72.22%	243.35%
Inventory
Prepaid Expenses	$393.0K	$535.0K	$765.0K
Receivables	$0.00	$70.00K	$237.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.900M	$8.626M	$17.45M
YoY Change	32677.78%	-74.85%	-63.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$100.0K	$94.00K	$166.0K
YoY Change	-66.67%	-81.2%	-69.6%
Goodwill	$1.034M	$1.034M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$400.0K	$415.0K	$13.00K
YoY Change	33.33%	38.33%	-65.79%
Total Long-Term Assets	$3.992M	$4.403M	$451.0K
YoY Change	5.36%	450.38%	-47.31%
TOTAL ASSETS
Total Short-Term Assets	$5.900M	$8.626M	$17.45M
Total Long-Term Assets	$3.992M	$4.403M	$451.0K
Total Assets	$9.892M	$13.03M	$17.90M
YoY Change	159.84%	-62.88%	-63.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$213.0K	$495.0K	$359.0K
YoY Change	124.21%	-50.5%	-39.36%
Accrued Expenses	$1.800M	$1.800M	$1.400M
YoY Change	-70.0%	-80.22%	-86.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$100.0K
YoY Change	-100.0%	-100.0%	0.0%
Total Short-Term Liabilities	$2.013M	$2.331M	$1.980M
YoY Change	-34.49%	-77.98%	-86.34%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities			$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.013M	$2.331M	$1.980M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.013M	$2.347M	$2.012M
YoY Change	-37.03%	-77.97%	-86.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.69M	-$8.915M	-$200.2M
YoY Change	515.62%	-95.33%
Common Stock	$20.57M	$19.59M	$213.5M
YoY Change	662.91%	-90.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.80M	$10.68M	$15.89M
YoY Change
Total Liabilities & Shareholders Equity	$9.892M	$13.03M	$17.90M
YoY Change	159.84%	-62.85%	-63.31%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2017 Q1
OPERATING ACTIVITIES
Net Income	-$3.740M	-$6.469M	-$205.0K
YoY Change	669.55%	2313.81%	-15.29%
Depreciation, Depletion And Amortization	$90.00K	$60.00K	$93.00K
YoY Change	125.0%	20.0%	66.07%
Cash From Operating Activities	-$3.630M	$6.050M	-$9.000M
YoY Change	-47.99%	-183.33%	-0.99%
INVESTING ACTIVITIES
Capital Expenditures			$1.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$270.0K	$2.150M	$9.470M
YoY Change	-97.41%	-74.65%	-250.08%
Cash From Investing Activities	$270.0K	$2.150M	$9.470M
YoY Change	-97.41%	-74.65%	-250.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	890.0K	1.130M	-20.00K
YoY Change
NET CHANGE
Cash From Operating Activities	-3.630M	6.050M	-9.000M
Cash From Investing Activities	270.0K	2.150M	9.470M
Cash From Financing Activities	890.0K	1.130M	-20.00K
Net Change In Cash	-2.470M	9.330M	9.000K
YoY Change	-171.8%	664.75%	-100.06%
FREE CASH FLOW
Cash From Operating Activities	-$3.630M	$6.050M	-$9.000M
Capital Expenditures			$1.000K
Free Cash Flow			-$9.001M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2532000
CY2017Q4	achv	Accrued Liabilities Clinical Current AccruedLiabilitiesClinicalCurrent	877000
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1028000
CY2016Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	829000
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	124000
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	20556000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12694000
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	7879000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9892000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2013000
CY2017Q4	us-gaap	Goodwill Goodwill	1034000
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11947932
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11956752
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1116000
CY2017	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	1272000
CY2017	achv	Contingent Value Rights Recovery ContingentValueRightsRecovery	200000
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-150000
CY2017	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-8610000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12000
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7002000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13634000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1738000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1235000
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3051000
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-504000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-407000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-1234000
	us-gaap	Net Income Loss NetIncomeLoss	-828000
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	4000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1000
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10583000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1230000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-827000
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.21
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-58.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-39.00
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4794421
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21230
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21230
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	0
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2000000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	1840000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	348000
CY2017	achv	Settlement Of Stockholder Loans With Related Parties SettlementOfStockholderLoansWithRelatedParties	2132000
CY2017	achv	Shares Issued Under Common Stock Subscription Value SharesIssuedUnderCommonStockSubscriptionValue	64000
CY2017	achv	Combined Shares Held By Equity Holders CombinedSharesHeldByEquityHolders	3000
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13048000
CY2017	achv	Stock Issued During Period Value Restricted Stock Unit Settlements Withheld And Retired To Treasury StockIssuedDuringPeriodValueRestrictedStockUnitSettlementsWithheldAndRetiredToTreasury	5000
CY2017	achv	Purchase Accounting Adjustments PurchaseAccountingAdjustments	44000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-828000
CY2017	us-gaap	Depreciation Depreciation	59000
CY2017	us-gaap	Adjustment For Amortization AdjustmentForAmortization	223000
CY2016	us-gaap	Adjustment For Amortization AdjustmentForAmortization	223000
CY2015	us-gaap	Adjustment For Amortization AdjustmentForAmortization	140000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	348000
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-407000
CY2017	achv	Contingent Value Rights Liability Recovery ContingentValueRightsLiabilityRecovery	200000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1349000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2000
CY2017	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	118000
CY2016	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	22000
CY2015	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	57000
CY2017	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2185000
CY2016	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	670000
CY2015	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	284000
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	877000
CY2017	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	458000
CY2017	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-1028000
CY2016	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	623000
CY2015	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	404000
CY2017	achv	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	-27000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9107000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-202000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-350000
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	64000
CY2017	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5000
CY2015	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	272000
CY2016	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	150000
CY2015	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	2683000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2001000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	150000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2411000
CY2017	achv	Cash Assumed In Reverse Merger CashAssumedInReverseMerger	12648000
CY2015	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	2000000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	12648000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2000000
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5541000
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-52000
CY2015	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	61000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15000
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67000
CY2014Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5556000
CY2016	achv	Interest Expense Accrued But Not Yet Paid InterestExpenseAccruedButNotYetPaid	26000
CY2015	achv	Interest Expense Accrued But Not Yet Paid InterestExpenseAccruedButNotYetPaid	11000
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and notes thereto. Actual results could differ from these estimates. Estimates and assumptions principally relate to estimates of the fair value of our warrant liability, the initial fair value and forfeiture rates of stock options issued to employees and consultants, the estimated compensation cost on performance restricted stock unit awards and clinical trial and manufacturing accruals, estimated useful lives of property, plant and equipment and estimates and assumptions in contingent liabilities. </p></div>
CY2017Q4	achv	Working Capital Balance WorkingCapitalBalance	3700000
CY2017	achv	Maturity Period Of Highly Liquid Investments To Be Considered As Cash Equivalent MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent	P3M
CY2017	achv	Description Of Maturity Period Of Financial Instruments To Be Considered As Short Term Investment DescriptionOfMaturityPeriodOfFinancialInstrumentsToBeConsideredAsShortTermInvestment	Greater than three months and less than one year
CY2017	achv	Average Period To Maturity For Portfolio Of Cash And Marketable Securities AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities	P0D
CY2017Q3	us-gaap	Finite Lived Intangible Assets Fair Value Disclosure FiniteLivedIntangibleAssetsFairValueDisclosure	8600000
CY2017Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P6Y
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	223000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	223000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	223000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	223000
CY2017Q4	achv	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	1640000
CY2017	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	150000
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	150000
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	272000
CY2016Q4	us-gaap	Cash Cash	15000
CY2017	achv	Maximum Maturity Period Of Cash And Cash Equivalents MaximumMaturityPeriodOfCashAndCashEquivalents	P90D
CY2017	achv	Maximum Maturity Period Of Short Term Investments MaximumMaturityPeriodOfShortTermInvestments	P1Y
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1144000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1085000
CY2017	achv	Period Of Not Utilizing Deferred Share Issuance Costs And Prepaid Amounts Related To Insurance PeriodOfNotUtilizingDeferredShareIssuanceCostsAndPrepaidAmountsRelatedToInsurance	P12M
CY2017	achv	Future Income Tax Rate Assumed For Deferred Tax Calculations FutureIncomeTaxRateAssumedForDeferredTaxCalculations	0.34
CY2016	achv	Future Income Tax Rate Assumed For Deferred Tax Calculations FutureIncomeTaxRateAssumedForDeferredTaxCalculations	0.34
CY2015	achv	Future Income Tax Rate Assumed For Deferred Tax Calculations FutureIncomeTaxRateAssumedForDeferredTaxCalculations	0.34
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4636000
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-504000
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-407000
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-174000
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	3158000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1052200
CY2017	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	314000
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1683000
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-14000
CY2017	achv	Income Tax Expense Benefit Excluding Adjustment For Reversal Of Deferred Tax Liability IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability	-3035000
CY2016	achv	Income Tax Expense Benefit Excluding Adjustment For Reversal Of Deferred Tax Liability IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability	-504000
CY2015	achv	Income Tax Expense Benefit Excluding Adjustment For Reversal Of Deferred Tax Liability IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability	-407000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	9900000
CY2016Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1300000
CY2017	achv	Unclaimed Tax Deductions Related To Scientific Research And Experimental Development Expenditures UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures	15500000
CY2017	achv	Tax Credit Carryforward Expiration Year Range Start TaxCreditCarryforwardExpirationYearRangeStart	2018
CY2017	achv	Tax Credit Carryforward Expiration Year Range End TaxCreditCarryforwardExpirationYearRangeEnd	2037
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	850000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	33524000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	496000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5506000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	51000
CY2017Q4	achv	Deferred Tax Assets Capitalized Research And Development Expenses DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses	3252000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	363000
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	246000
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	43429000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	859000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42914000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	46000
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	515000
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	813000
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	513000
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	937000
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2000
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	515000
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	937000
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	124000
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	715000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	699000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	683000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	16000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	16000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	715000
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	700000
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2016Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2017	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	5464
CY2016	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0195
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8606
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.09
CY2017	achv	Share Based Compensation Arrangement By Share Based Payment Award Options Additions On Reverse Takeover ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionsOnReverseTakeover	113451
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0
CY2017	achv	Number Of Warrants Exercised NumberOfWarrantsExercised	0
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21230
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-39.00
CY2017Q4	us-gaap	Contractual Obligation ContractualObligation	602000
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1700000
CY2016Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	7.99
CY2016	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P9Y4M13D
CY2016Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	62824
CY2016Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	91.79
CY2016	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y11M12D
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2000000
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	600000
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	19543
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	30461
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1115647
CY2017	achv	Share Based Compensation Arrangements By Share Based Payment Award Options Additions On Reverse Takeover In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAdditionsOnReverseTakeoverInPeriodWeightedAverageExercisePrice	96.38
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.89
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	114.53
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	92.72
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.99
CY2016Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1115647
CY2017Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	286000
CY2017Q4	us-gaap	Contractual Obligation Due In Second And Third Year ContractualObligationDueInSecondAndThirdYear	291000
CY2017Q4	us-gaap	Contractual Obligation Due In Fourth And Fifth Year ContractualObligationDueInFourthAndFifthYear	25000
CY2017	achv	Expiration Of Operating Lease Agreement ExpirationOfOperatingLeaseAgreement	2018-09
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	600000
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2800000
CY2017Q4	us-gaap	Guarantee Obligations Current Carrying Value GuaranteeObligationsCurrentCarryingValue	0
CY2017	achv	Indemnification Expense IndemnificationExpense	0
CY2017Q3	achv	Number Of Terminated Senior Executives NumberOfTerminatedSeniorExecutives	1
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61000
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62000
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	825000
CY2017Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2153000
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	260000
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	96000
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1546000
CY2017Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1629000
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	321000
CY2017Q2	us-gaap	Costs And Expenses CostsAndExpenses	158000
CY2017Q3	us-gaap	Costs And Expenses CostsAndExpenses	2371000
CY2017Q4	us-gaap	Costs And Expenses CostsAndExpenses	3782000
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8000
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11000
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7025000
CY2017Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	42000
CY2017Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-124000
CY2017Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2927000
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-205000
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-169000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-6469000
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-3740000
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.66
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.96
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-486000
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.90
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6000
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7000
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7000
CY2016Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4000
CY2016Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-118000
CY2016Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-122000
CY2016Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-137000
CY2016Q4	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-127000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-242000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-238000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-268000
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65000
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72000
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69000
CY2016Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80000
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	289000
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	281000
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	329000
CY2016Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	529000
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	354000
CY2016Q2	us-gaap	Costs And Expenses CostsAndExpenses	353000
CY2016Q3	us-gaap	Costs And Expenses CostsAndExpenses	398000
CY2016Q4	us-gaap	Costs And Expenses CostsAndExpenses	609000
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-11.40
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-11.21
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-12.62
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-22.89

Files In Submission

Name	View Source	Status
0001564590-18-004159-index-headers.html	Edgar Link	pending
0001564590-18-004159-index.html	Edgar Link	pending
0001564590-18-004159.txt	Edgar Link	pending
0001564590-18-004159-xbrl.zip	Edgar Link	pending
achv-10k_20171231.htm	Edgar Link	pending
achv-20171231.xml	Edgar Link	completed
achv-20171231.xsd	Edgar Link	pending
achv-20171231_cal.xml	Edgar Link	unprocessable
achv-20171231_def.xml	Edgar Link	unprocessable
achv-20171231_lab.xml	Edgar Link	unprocessable
achv-20171231_pre.xml	Edgar Link	unprocessable
achv-ex1020_542.htm	Edgar Link	pending
achv-ex107b_794.htm	Edgar Link	pending
achv-ex107c_793.htm	Edgar Link	pending
achv-ex211_6.htm	Edgar Link	pending
achv-ex231_9.htm	Edgar Link	pending
achv-ex311_8.htm	Edgar Link	pending
achv-ex312_11.htm	Edgar Link	pending
achv-ex321_10.htm	Edgar Link	pending
achv-ex322_7.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g2018030122194446930973.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACHV
ACHIEVE LIFE SCIENCES, INC. Stock $achv

2017 Q4 Form 10-K Financial Statement

#000156459018004159 Filed on March 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACHV ACHIEVE LIFE SCIENCES, INC. Stock $achv

2017 Q4 Form 10-K Financial Statement

#000156459018004159 Filed on March 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACHV
ACHIEVE LIFE SCIENCES, INC. Stock $achv